Nutramax establishes Cosamin ASU efficacy through open-label pilot study

EDGEWOOD, Md. - Nutramax Laboratories Consumer Care on Monday announced the results of a six-week, open-label pilot study that found Cosamin ASU, the company's advanced joint health formulation, is effective in reducing joint discomfort and cartilage breakdown.

 

The study, carried out by researchers at the University of Missouri, also included clinical assessments which found that Cosamin ASU may be associated with improvements in measures of function and quality of life.

 

"This is the first study to show that serum and urine biomarkers can effectively detect improvements in a comprehensive spectrum of validated clinical outcome measures of pain, function and quality of life in patients receiving Cosamin ASU," stated James Cook, principle study investigator and director, University of Missouri Comparative Orthopaedic Laboratory, Mizzou BioJoint Center.

 

"This comprehensive pilot analysis provides us with additional support of the efficacy of Cosamin ASU for promoting joint health," commented Brian Cornblatt, medical director of Nutramax Laboratories Consumer Care. "Using biomarkers to assess our products in the human clinical trial setting allows us to translate our in vitro findings. For years we have studied the effects of our novel formulations on well-recognized tissue culture models. To see these same biomarkers associated with joint discomfort and cartilage breakdown decrease significantly in a clinical trial setting is reassuring as we carefully seek to develop our products backed by sound and robust science."

 

Cosamin ASU is a combination of glucosamine hydrochloride, chondroitin sulfate, avocado/soybean unsaponifiables, 3-O-acetyl-11-keto-boswellic acid and decaffeinated green tea extract.

 

Subsequent research plans include a multi-center, placebo-controlled clinical study aimed at further bridging clinical assessments of Cosamin ASU with validated biomarkers.